Oncology Clinical Trials in Chicago, IL
As of September 2026, 395 paid clinical trials are recruiting for Oncology in Chicago, Illinois. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Chicago
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
398 clinical trials for Oncology
·Clear filters·A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Top Research Study Locations in Chicago
Researchers run research studies in Chicago, IL at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Northwestern University | Metastatic Malignant Solid Neoplasm, Prostate Adenocarcinoma, Stage IV Lung Cancer AJCC v8 | 345 |
| University of Chicago | Heart Failure, Peripheral Artery Disease, Gastric Cancer | 184 |
| Rush University Medical Center | Angelman Syndrome, Degenerative Disc Disease, Atrial Fibrillation | 157 |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Diffuse Intrinsic Pontine Glioma, High Grade Glioma, WHO Grade III Glioma | 110 |
| University of Chicago Medical Center | Endometrial Cancer, Breast Cancer, Kidney Stone | 98 |
| University of Chicago Comprehensive Cancer Center | Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | 89 |
| Northwestern Memorial Hospital | Multiple Sclerosis, Heart Failure, Inguinal Hernia Bilateral | 85 |
| University of Illinois | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Breast Cancer | 84 |
| University of Illinois at Chicago | Multiple Sclerosis, Carcinoma, Non-Small-Cell Lung, Chronic Stroke | 70 |
| Advocate Illinois Masonic Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma | 48 |
| The University of Chicago | Head and Neck Cancer, Malnutrition, AML With Gene Mutations | 44 |
| Shirley Ryan AbilityLab | Stroke, Multiple Sclerosis, Spinal Cord Injuries | 36 |
| University of Illinois Chicago | Breast Cancer Early Stage Breast Cancer (Stage 1-3), Type 1 Diabetes (T1D), ASCVD | 34 |
| Lurie Children's Hospital-Chicago | Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm | 32 |
| Northwestern University Feinberg School of Medicine | Peripheral Artery Disease, Aging, Depression | 29 |
| Rush MD Anderson Cancer Center | Stage IVB Prostate Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | 25 |
| John H Stroger Jr Hospital of Cook County | Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Anatomic Stage I Breast Cancer AJCC v8 | 24 |
| Northwestern Medicine | AML - Acute Myeloid Leukemia, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS) | 23 |
| Rush University | Preterm, AV Block, Acute Kidney Injury | 22 |
| University of Illinois Cancer Center | Breast Cancer, Gastric Cancer, Cervical Cancer | 22 |
| The University of Chicago Medical Center | Systemic Sclerosis, Acute Myeloid Leukemia, Interstitial Lung Diseases | 21 |
| University of Chicago Medicine Comprehensive Cancer Center | Carcinoma, Squamous Cell, Prostate Cancer, Acute Leukemia | 20 |
| Lurie Children's Hospital | Congenital Heart Disease (CHD), ACL Injury, ACL Tear | 18 |
| University of Chicago Medicine | Advanced Solid Tumor, Lung Cancer, Ulcerative Colitis | 16 |
| Lurie Children's Hospital of Chicago | Acute Kidney Injury, Duchenne Muscular Dystrophy, Neurofibromatosis 1 | 14 |
Active & Upcoming Studies in Chicago (2026)
Recruiting trials in Chicago grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (600 active studies)
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma · Phase 1 · Northwestern University
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial · Phase 2 · National Cancer Institute (NCI)
Neurology & pain (148 active studies)
- Use of a Vibration Tool for Postoperative Pain Control in Distal Radius Fractures · Northwestern University
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · Yale University
Cardiovascular (116 active studies)
- Mobile Health Management of Hypertension · University of Chicago
- PRECISION-CPR: PRecision-Controlled Ventilation in CPR · Rush University Medical Center
Diabetes & metabolic (108 active studies)
Mental health & behavior (77 active studies)
HIV / STI (33 active studies)
- A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs · NYU Langone Health
- A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Pediatric (33 active studies)
- Reducing Disparities in Knee Arthroscopy for Adolescents · Ann & Robert H Lurie Children's Hospital of Chicago
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · Justin Ryder
Vaccines (19 active studies)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age · Phase 3 · GlaxoSmithKline
- A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) · Phase 1, Phase 2 · AstraZeneca
Eye & vision (9 active studies)
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) · Phase 3 · Adverum Biotechnologies, Inc.
- A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · Astellas Pharma Global Development, Inc.
Common conditions studied in Chicago
- Breast Cancer (35 active studies)
- Obesity (27 active studies)
- Stroke (25 active studies)
- Heart Failure (24 active studies)
- Acute Myeloid Leukemia (23 active studies)
- Hypertension (22 active studies)
Leading research sponsors in Chicago
- Northwestern University
- University of Chicago
- University of Illinois at Chicago
- National Cancer Institute (NCI)
- Rush University Medical Center
Frequently asked questions
How many paid clinical trials are currently recruiting in Chicago?
There are approximately 2,146 recruiting clinical trials in Chicago, Illinois listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Chicago pay participants?
Most recruiting trials in Chicago compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Chicago?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Chicago?
The most common conditions under active study in Chicago include Breast Cancer (35), Obesity (27), Stroke (25), Heart Failure (24), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Chicago?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Chicago on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Chicago?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Chicago?
Recruiting research sites in Chicago include Northwestern University, University of Chicago, Rush University Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Chicago right now?
The largest active categories in Chicago are Cancer & tumors (600), Neurology & pain (148), Cardiovascular (116). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.